Myocardial reverse remodeling: How far can we rewind?

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 310, Issue 11, 2016, Pages H1402-H1422

  Rodrigues, Patrícia G ^a   Leite Moreira, Adelino F ^a   Falcão Pires, Inês ^a  

^a University of Porto   (Portugal)

Author keywords

Diastolic dysfunction; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Left ventricle hypertrophy; Myocardial reverse remodeling

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM BINDING PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CARVEDILOL; CONNECTIN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; IVABRADINE; METOPROLOL SUCCINATE; MYOSIN BINDING PROTEIN C; NEBIVOLOL; PARVALBUMIN; PERINDOPRIL; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; RANOLAZINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SACUBITRIL PLUS VALSARTAN; SILDENAFIL; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VERICIGUAT; CARDIOVASCULAR AGENT;

AORTA STENOSIS; ATRIAL FIBRILLATION; CARDIAC MUSCLE CELL; CLINICAL TRIAL (TOPIC); COMORBIDITY; DEVICE THERAPY; DIABETES MELLITUS; DIASTOLIC DYSFUNCTION; DRUG EFFICACY; EXERCISE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; INFLAMMATION; ISCHEMIC HEART DISEASE; LEFT VENTRICULAR ASSIST DEVICE; META ANALYSIS (TOPIC); MYOCARDIAL REVERSE REMODELING; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIAC MUSCLE; CONVALESCENCE; DRUG DESIGN; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CARDIOVASCULAR AGENTS; DRUG DESIGN; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MOLECULAR TARGETED THERAPY; MYOCARDIUM; RECOVERY OF FUNCTION; SIGNAL TRANSDUCTION; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84983762736     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00696.2015     Document Type: Review

References (282)

1. Abbate A, Arena R, Abouzaki N, Van Tassell BW, Canada J, Shah K, Biondi-Zoccai G, Voelkel NF. Heart failure with preserved ejection fraction: refocusing on diastole. Int J Cardiol 179: 430–440, 2015.
2. Al-Thani HA, El-Menyar A, Zubaid M, Rashed WA, Ridha M, Almahmeed W, Sulaiman K, Al-Motarreb A, Amin H, Al Suwaidi J. Peripheral arterial disease in patients presenting with acute coronary syndrome in six middle eastern countries. Int J Vasc Med 2011: 815902, 2011.
3. Alegre-Cebollada J, Kosuri P, Giganti D, Eckels E, Rivas-Pardo JA, Hamdani N, Warren CM, Solaro RJ, Linke WA, Fernandez JM. S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding. Cell 156: 1235–1246, 2014.
4. Allen DG, Orchard CH. Myocardial contractile function during ischemia and hypoxia. Circ Res 60: 153–168, 1987.
5. Anguita M, Castillo JC, Ruiz M, Castillo F, Jimenez-Navarro M, Crespo M, Alonso-Pulpon L, de Teresa E, Castro-Beiras A, Roig E, Artigas R, Zapata A, de Ullibarri IL, Muniz J. Differences in outcome of heart failure with preserved or depressed systolic function in patients older than 70 years who receive beta blockers. Rev Esp Cardiol (Engl Ed) 65: 22–28, 2012.
6. Asp ML, Martindale JJ, Heinis FI, Wang W, Metzger JM. Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies. Biochim Biophys Acta 1833: 895–900, 2013.
7. Asrar ul Haq M, Wong C, Mutha V, Anavekar N, Lim K, Barlis P, Hare DL. Therapeutic interventions for heart failure with preserved ejection fraction: a summary of current evidence. World J Cardiol 6: 67–76, 2014.
8. Badano LP, Albanese MC, De Biaggio P, Rozbowsky P, Miani D, Fresco C, Fioretti PM. Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction. J Am Soc Echocardiogr 17: 253–261, 2004.
9. Barbone A, Holmes JW, Heerdt PM, The AH, Naka Y, Joshi N, Daines M, Marks AR, Oz MC, Burkhoff D. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling. Circulation 104: 670–675, 2001.
10. 2 + sensitivity and crossbridge cycling. J Biol Chem 285: 5674–5682, 2010.
11. Bavishi C, Chatterjee S, Ather S, Patel D, Messerli FH. Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Fail Rev 20: 193–201, 2015.
12. Beaumont J, Lopez B, Hermida N, Schroen B, San Jose G, Heymans S, Valencia F, Gomez-Doblas JJ, De Teresa E, Diez J, Gonzalez A. microRNA-122 down-regulation may play a role in severe myocardial fibrosis in human aortic stenosis through TGF-beta1 up-regulation. Clin Sci 126: 497–506, 2014.
13. Bergstrom A, Andersson B, Edner M, Nylander E, Persson H, Dahlstrom U. Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function. Results of the Swedish Doppler-echocardiographic study (SWEDIC). Eur J Heart Fail 6: 453–461, 2004.
14. Bernardo BC, Nguyen SS, Winbanks CE, Gao XM, Boey EJ, Tham YK, Kiriazis H, Ooi JY, Porrello ER, Igoor S, Thomas CJ, Grego-revic P, Lin RC, Du XJ, McMullen JR. Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J 28: 5097–5110, 2014.
15. Bers DM, Shannon TR. Calcium movements inside the sarcoplasmic reticulum of cardiac myocytes. J Mol Cell Cardiol 58: 59–66, 2013.
16. Biederman RW, Magovern JA, Grant SB, Williams RB, Yamrozik JA, Vido DA, Rathi VK, Rayarao G, Caruppannan K, Doyle M. LV reverse remodeling imparted by aortic valve replacement for severe aortic stenosis; is it durable? A cardiovascular MRI study sponsored by the American Heart Association. J Cardiothorac Surg 6: 53, 2011.
17. Bishu K, Hamdani N, Mohammed SF, Kruger M, Ohtani T, Ogut O, Brozovich FV, Burnett JC Jr, Linke WA, Redfield MM. Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation 124: 2882–2891, 2011.
18. Bjornstad JL, Sjaastad I, Nygard S, Hasic A, Ahmed MS, Attrama-dal H, Finsen AV, Christensen G, Tonnessen T. Collagen isoform shift during the early phase of reverse left ventricular remodelling after relief of pressure overload. Eur Heart J 32: 236–245, 2011.
19. Bjornstad JL, Skrbic B, Sjaastad I, Bjornstad S, Christensen G, Tonnessen T. A mouse model of reverse cardiac remodelling following banding-debanding of the ascending aorta. Acta Physiol 205: 92–102, 2012.
20. Blanton RM, Takimoto E, Aronovitz M, Thoonen R, Kass DA, Karas RH, Mendelsohn ME. Mutation of the protein kinase I alpha leucine zipper domain produces hypertension and progressive left ventricular hypertrophy: a novel mouse model of age-dependent hypertensive heart disease. J Gerontol A Biol Sci Med Sci 68: 1351–1355, 2013.
21. Blanton RM, Takimoto E, Lane AM, Aronovitz M, Piotrowski R, Karas RH, Kass DA, Mendelsohn ME. Protein kinase gialpha inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc 1: e003731, 2012.
22. Borbely A, Falcao-Pires I, van Heerebeek L, Hamdani N, Edes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 104: 780–786, 2009.
23. Borbely A, Papp Z, Edes I, Paulus WJ. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 61: 139–145, 2009.
24. Borbely A, van der Velden J, Papp Z, Bronzwaer JG, Edes I, Stienen GJ, Paulus WJ. Cardiomyocyte stiffness in diastolic heart failure. Circulation 111: 774–781, 2005.
25. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, Kass DA. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 114: 2138–2147, 2006.
26. Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, Redfield MM. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol 56: 845–854, 2010.
27. Braunwald E. The war against heart failure: the Lancet lecture. Lancet 385: 812–824, 2015.
28. Bray N. Cardiovascular disease: PDE9A inhibition mends broken hearts. Nat Rev Drug Discov 14: 310, 2015.
29. Brinks H, Rohde D, Voelkers M, Qiu G, Pleger ST, Herzog N, Rabinowitz J, Ruhparwar A, Silvestry S, Lerchenmuller C, Mather PJ, Eckhart AD, Katus HA, Carrel T, Koch WJ, Most P. S100A1 genetically targeted therapy reverses dysfunction of human failing car-diomyocytes. J Am Coll Cardiol 58: 966–973, 2011.
30. Bujak M, Frangogiannis NG. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184–195, 2007.
31. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O’Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail 2: 97–112, 2014.
32. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibro-blasts. J Mol Cell Cardiol 29: 1947–1958, 1997.
33. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, Rubin SM, Ding J, Simonsick EM, Harris TB, Pahor M. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 108: 2317–2322, 2003.
34. Cleland JG, Taylor J, Freemantle N, Goode KM, Rigby AS, Tendera M. Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study. Eur J Heart Fail 14: 487–494, 2012.
35. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 27: 2338–2345, 2006.
36. Cleutjens JP. The role of matrix metalloproteinases in heart disease. Cardiovasc Res 32: 816–821, 1996.
37. Cocco G, Rousseau MF, Bouvy T, Cheron P, Williams G, Detry JM, Pouleur H. Effects of a new metabolic modulator, ranolazine, on exercise tolerance in angina pectoris patients treated with beta-blocker or diltiazem. J Cardiovasc Pharmacol 20: 131–138, 1992.
38. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling–concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Re-modeling. J Am Coll Cardiol 35: 569–582, 2000.
39. Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, Martos R, Baugh JA, Ledwidge MT, McDonald KM. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 13: 1087–1095, 2011.
40. Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Bohm M, Dei Cas L. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 14: 219–225, 2012.
41. Coulton AT, Stelzer JE. Cardiac myosin binding protein C and its phosphorylation regulate multiple steps in the cross-bridge cycle of muscle contraction. Biochemistry 51: 3292–3301, 2012.
42. da Costa Martins PA, Salic K, Gladka MM, Armand AS, Leptidis S, el Azzouzi H, Hansen A, Coenen-de Roo CJ, Bierhuizen MF, van der Nagel R, van Kuik J, de Weger R, de Bruin A, Condorelli G, Arbones ML, Eschenhagen T, De Windt LJ. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineu-rin/NFAT signalling. Nat Cell Biol 12: 1220–1227, 2010.
43. Dai DF, Hsieh EJ, Liu Y, Chen T, Beyer RP, Chin MT, MacCoss MJ, Rabinovitch PS. Mitochondrial proteome remodelling in pressure over-load-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res 93: 79–88, 2012.
44. Dai DF, Johnson SC, Villarin JJ, Chin MT, Nieves-Cintron M, Chen T, Marcinek DJ, Dorn GW, Kang YJ 2nd, Prolla TA, Santana LF, Rabinovitch PS. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Cardiovasc Res 108: 837–846, 2011.
45. Dai DF, Santana LF, Vermulst M, Tomazela DM, Emond MJ, MacCoss MJ, Gollahon K, Martin GM, Loeb LA, Ladiges WC, Rabinovitch PS. Overexpression of catalase targeted to mitochondria attenuates murine cardiac aging. Circulation 119: 2789–2797, 2009.
46. Das S, Bedja D, Campbell N, Dunkerly B, Chenna V, Maitra A, Steenbergen C. miR-181c regulates the mitochondrial genome, bioen-ergetics, and propensity for heart failure in vivo. PLoS One 9: e96820, 2014.
47. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 97: 2316–2322, 1998.
48. Diwan A, Wansapura J, Syed FM, Matkovich SJ, Lorenz JN, Dorn GW 2nd. Nix-mediated apoptosis links myocardial fibrosis, cardiac remodeling, and hypertrophy decompensation. Circulation 117: 396–404, 2008.
49. Dobre D, van Veldhuisen DJ, DeJongste MJ, Lucas C, Cleuren G, Sanderman R, Ranchor AV, Haaijer-Ruskamp FM. Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. Eur J Heart Fail 9: 280–286, 2007.
50. Doenst T, Pytel G, Schrepper A, Amorim P, Farber G, Shingu Y, Mohr FW, Schwarzer M. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc Res 86: 461–470, 2010.
51. Dong DL, Chen C, Huo R, Wang N, Li Z, Tu YJ, Hu JT, Chu X, Huang W, Yang BF. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for pro-gressive cardiac hypertrophy. Hypertension 55: 946–952, 2010.
52. Dong S, Ma W, Hao B, Hu F, Yan L, Yan X, Wang Y, Chen Z, Wang Z. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2. Int J Clin Exp Pathol 7: 565–574, 2014.
53. Dougherty AH, Naccarelli GV, Gray EL, Hicks CH, Goldstein RA. Congestive heart failure with normal systolic function. Am J Cardiol 54: 778–782, 1984.
54. Drakos SG, Wever-Pinzon O, Selzman CH, Gilbert EM, Alharethi R, Reid BB, Saidi A, Diakos NA, Stoker S, Davis ES, Movsesian M, Li DY, Stehlik J, Kfoury AG. Magnitude and time course of changes induced by continuous-flow left ventricular assist device unloading in chronic heart failure: insights into cardiac recovery. J Am Coll Cardiol 61: 1985–1994, 2013.
55. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibi-tion of the renin-angiotensin system. Hypertension 56: 865–870, 2010.
56. Duarte-Costa S, Castro-Ferreira R, Neves JS, Leite-Moreira AF. S100A1: a major player in cardiovascular performance. Physiol Res 63: 669–681, 2014.
57. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104: 170–178, 176p following 178, 2009.
58. Edelmann F, Gelbrich G, Dungen HD, Frohling S, Wachter R, Stahrenberg R, Binder L, Topper A, Lashki DJ, Schwarz S, Herr-mann-Lingen C, Loffler M, Hasenfuss G, Halle M, Pieske B. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 58: 1780–1791, 2011.
59. Edelmann F, Wachter R, Schmidt AG, Kraigher-Krainer E, Colan-tonio C, Kamke W, Duvinage A, Stahrenberg R, Durstewitz K, Loffler M, Dungen HD, Tschope C, Herrmann-Lingen C, Halle M, Hasenfuss G, Gelbrich G, Pieske B. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309: 781–791, 2013.
60. Emter CA, Baines CP. Low-intensity aerobic interval training attenu-ates pathological left ventricular remodeling and mitochondrial dysfunc-tion in aortic-banded miniature swine. Am J Physiol Heart Circ Physiol 299: H1348–H1356, 2010.
61. + current in miniature swine with LV hypertrophy. Am J Physiol Heart Circ Physiol 301: H1687–H1694, 2011.
62. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, Molkentin JD, Drexler H, Wollert KC. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci USA 99: 11363–11368, 2002.
63. Fielitz J, Hein S, Mitrovic V, Pregla R, Zurbrugg HR, Warnecke C, Schaper J, Fleck E, Regitz-Zagrosek V. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37: 1443–1449, 2001.
64. Fielitz J, Leuschner M, Zurbrugg HR, Hannack B, Pregla R, Hetzer R, Regitz-Zagrosek V. Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis. J Mol Med 82: 809–820, 2004.
65. Filippatos G, Farmakis D, Parissis J, Lekakis J. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med 13: 35, 2015.
66. Flarsheim CE, Grupp IL, Matlib MA. Mitochondrial dysfunction accompanies diastolic dysfunction in diabetic rat heart. Am J Physiol Heart Circ Physiol 271: H192–H202, 1996.
67. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Park-homenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Bohm M, Anker SD, Thompson SG, Poole-Wilson PA. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215–225, 2005.
68. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O’Connor CM, Sun JL, Yancy CW, Young JB. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTI-MIZE-HF Registry. J Am Coll Cardiol 50: 768–777, 2007.
69. Forfia PR, Borlaug BA. Letter by Forfia and Borlaug regarding article, “Pulmonary hypertension in heart failure with preserved ejection frac-tion: a target of phosphodiesterase-5 inhibition in a 1-year study”. Circulation 125: e408; author reply e409-410, 2012.
70. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62: 525–563, 2010.
71. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N. Myocardial microvascular inflammatory en-dothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 4: 312–324, 2016.
72. Fu TC, Yang NI, Wang CH, Cherng WJ, Chou SL, Pan TL, Wang JS. Aerobic interval training elicits different hemodynamic adaptations between heart failure patients with preserved and reduced ejection fraction. Am J Phys Med Rehabil 5: 15–27, 2016.
73. Fukuta H, Little WC. Observational studies of statins in heart failure with preserved systolic function. Heart Fail Clin 4: 209–216, 2008.
74. Fukuta H, Sane DC, Brucks S, Little WC. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112: 357–363, 2005.
75. Gaasch WH. Left ventricular radius to wall thickness ratio. Am J Cardiol 43: 1189–1194, 1979.
76. Galema TW, Yap SC, Soliman OI, Van Thiel RJ, Cate FJ, Branden-burg HJ, Bogers AJ, Simoons ML, Geleijnse ML. Recovery of long-axis left ventricular function after aortic valve replacement in patients with severe aortic stenosis. Echocardiography 27: 1177–1181, 2010.
77. Gautel M, Zuffardi O, Freiburg A, Labeit S. Phosphorylation switches specific for the cardiac isoform of myosin binding protein-C: a modulator of cardiac contraction? EMBO J 14: 1952–1960, 1995.
78. Gavina C. Determinants of left ventricular hypertrophy before and after surgical treatment of aortic stenosis: clinical, morphofunctional, genetic and molecular correlations. In: Faculdade de Medicina. Porto, Portugal: Faculdade de Medicina da Universidade do Porto, 2015, p. 165
79. Gavina C, Falcao-Pires I, Rocha-Goncalves F, Leite-Moreira A. Left ventricular hypertrophy in isolated aortic stenosis: primetime for the ventricle. Curr Pharm Biotech 13: 2503–2514, 2012.
80. Gavina C, Falcao-Pires I, Rodrigues J, Marinho B, Goncalves N, Lopes R, Amorim MJ, Almeida J, Pinho P, Goncalves A, Rocha-Goncalves F, Leite-Moreira A. Load independent impairment of re-verse remodeling after valve replacement in hypertensive aortic stenosis patients. Int J Cardiol 170: 324–330, 2014.
81. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 115: 500–508, 2005.
82. Glezeva N, Baugh JA. Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev 19: 681–694, 2014.
83. Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem 285: 28938–28945, 2010.
84. Gordon B, McDiarmid A, MacGowan G. Letter by Gordon et al. regarding article, “Pulmonary hypertension in heart failure with pre-served ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study”. Circulation 125: e406; author reply e409-410, 2012.
85. Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94: 1621–1628, 1994.
86. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 91: 2573–2581, 1995.
87. Grutzner A, Garcia-Manyes S, Kotter S, Badilla CL, Fernandez JM, Linke WA. Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence. Biophys J 97: 825–834, 2009.
88. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodi-esterase-5 inhibition in a 1-year study. Circulation 124: 164–174, 2011.
89. Gurha P, Abreu-Goodger C, Wang T, Ramirez MO, Drumond AL, van Dongen S, Chen Y, Bartonicek N, Enright AJ, Lee B, Kelm RJ Jr, Reddy AK, Taffet GE, Bradley A, Wehrens XH, Entman ML, Rodriguez A. Targeted deletion of microRNA-22 promotes stress-induced cardiac dilation and contractile dysfunction. Circulation 125: 2751–2761, 2012.
90. Gurha P, Wang T, Larimore AH, Sassi Y, Abreu-Goodger C, Ramirez MO, Reddy AK, Engelhardt S, Taffet GE, Wehrens XH, Entman ML, Rodriguez A. microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription. PLoS One 8: e75882, 2013.
91. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovas Res 97: 464–471, 2013.
92. Hamdani N, Franssen C, Lourenco A, Falcao-Pires I, Fontoura D, Leite S, Plettig L, Lopez B, Ottenheijm CA, Becher PM, Gonzalez A, Tschope C, Diez J, Linke WA, Leite-Moreira AF, Paulus WJ. Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail 6: 1239–1249, 2013.
93. Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, Kruger M, Backs J, Linke WA. Crucial role for Ca2(+)/ calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res 112: 664–674, 2013.
94. Hamdani N, Paulus WJ. Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime. Circulation 128: 5–8, 2013.
95. Harding JD, Piacentino V, Gaughan JP 3rd, Houser SR, Margulies KB. Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure. Circulation 104: 1241–1247, 2001.
96. Heerdt PM, Holmes JW, Cai B, Barbone A, Madigan JD, Reiken S, Lee DL, Oz MC, Marks AR, Burkhoff D. Chronic unloading by left ventricular assist device reverses contractile dysfunction and alters gene expression in end-stage heart failure. Circulation 102: 2713–2719, 2000.
97. Heinzel FR, Hohendanner F, Jin G, Sedej S, Edelmann F. Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol 119: 1233–1242, 2015.
98. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112: 1136–1144, 2005.
99. Hidalgo C, Hudson B, Bogomolovas J, Zhu Y, Anderson B, Greaser M, Labeit S, Granzier H. PKC phosphorylation of titin’s PEVK element: a novel and conserved pathway for modulating myocardial stiffness. Circ Res 105: 631–638, 617 p following 638, 2009.
100. Hoendermis ES, Liu LC, Hummel YM, van der Meer P, de Boer RA, Berger RM, van Veldhuisen DJ, Voors AA. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a random-ized controlled trial. Eur Heart J 36: 2565–2573, 2015.
101. Hoshikawa E, Matsumura Y, Kubo T, Okawa M, Yamasaki N, Kitaoka H, Furuno T, Takata J, Doi YL. Effect of left ventricular reverse remodeling on long-term prognosis after therapy with angioten-sin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 107: 1065–1070, 2011.
102. Hou J, Kang YJ. Regression of pathological cardiac hypertrophy: signaling pathways and therapeutic targets. Pharmacol Ther 135: 337–354, 2012.
103. Hua Y, Zhang Y, Ren J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and mi-croRNA-133a. J Cell Mol Med 16: 83–95, 2012.
104. 2+sensitivity and arrhythmia susceptibility. J Cell Mol Med 48: 824–833, 2010.
105. Ibrahim M, Navaratnarajah M, Siedlecka U, Rao C, Dias P, Mosh-kov AV, Gorelik J, Yacoub MH, Terracciano CM. Mechanical un-loading reverses transverse tubule remodelling and normalizes local Ca(2+) induced Ca(2+)release in a rodent model of heart failure. Eur J Heart Fail 14: 571–580, 2012.
106. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29: 2193–2204, 2009.
107. Imanaka K, Kohmoto O, Nishimura S, Yokote Y, Kyo S. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis. Eur J Cardiothorac Surg 27: 994–999, 2005.
108. Ishikawa K, Aguero J, Oh JG, Hammoudi N, Fish LA, Leonardson L, Picatoste B, Santos-Gallego CG, Fish KM, Hajjar RJ. Increased stiffness is the major early abnormality in a pig model of severe aortic stenosis and predisposes to congestive heart failure in the absence of systolic dysfunction. J Am Heart Assoc 4: e001925, 2015.
109. Iwahashi N, Nakatani S, Kanzaki H, Hasegawa T, Abe H, Kitakaze M. Acute improvement in myocardial function assessed by myocardial strain and strain rate after aortic valve replacement for aortic stenosis. J Am Soc Echocardiogr 19: 1238–1244, 2006.
110. Jameel MN, Zhang J. Myocardial energetics in left ventricular hyper-trophy. Curr Cardiol Rev 5: 243–250, 2009.
111. Jamous FG. Letter by Jamous regarding article, “Pulmonary hyperten-sion in heart failure with preserved ejection fraction: a target of phos-phodiesterase-5 inhibition in a 1-year study”. Circulation 125: e407; author reply e409-410, 2012.
112. Jeong EM, Dudley SC Jr. New diagnostic and therapeutic possibilities for diastolic heart failure. R I Med J 97: 35–37, 2014.
113. Jumean MF, Konstam MA. Heart failure with preserved ejection fraction: what is in a name? Cardiol Rev 23: 161–167, 2015.
114. Kalogeropoulos A, Georgiopoulou V, Psaty BM, Rodondi N, Smith AL, Harrison DG, Liu Y, Hoffmann U, Bauer DC, Newman AB, Kritchevsky SB, Harris TB, Butler J. Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study. J Am Coll Cardiol 55: 2129–2137, 2010.
115. Kass DA, Baughman KL, Pak PH, Cho PW, Levin HR, Gardner TJ, Halperin HR, Tsitlik JE, Acker MA. Reverse remodeling from cardio-myoplasty in human heart failure. External constraint versus active assist. Circulation 91: 2314–2318, 1995.
116. Katz AM, Rolett EL. Heart failure: when form fails to follow function. Eur Heart J 37: 449–454, 2016.
117. Katz DH, Beussink L, Sauer AJ, Freed BH, Burke MA, Shah SJ. Prevalence, clinical characteristics, and outcomes associated with eccen-tric versus concentric left ventricular hypertrophy in heart failure with preserved ejection fraction. Am J Cardiol 112: 1158–1164, 2013.
118. Kawaguchi M, Hay I, Fetics B, Kass DA. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limita-tions. Circulation 107: 714–720, 2003.
119. Kehat I, Molkentin JD. Molecular pathways underlying cardiac remod-eling during pathophysiological stimulation. Circulation 122: 2727–2735, 2010.
120. Khafaji HA, Sulaiman K, Singh R, AlHabib KF, Asaad N, Alsheikh-Ali A, Al-Jarallah M, Bulbanat B, AlMahmeed W, Ridha M, Baz-argani N, Amin H, Al-Motarreb A, AlFaleh H, Elasfar A, Pan-duranga P, Al Suwaidi J. Clinical characteristics, precipitating factors, management and outcome of patients with prior stroke hospitalised with heart failure: an observational report from the Middle East. BMJ Open 5: e007148, 2015.
121. Khan R, Sheppard R. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology 118: 10–24, 2006.
122. Kim JO, Song DW, Kwon EJ, Hong SE, Song HK, Min CK, Kim do H. miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. PLoS One 10: e0122509, 2015.
123. Kitzman DW. Exercise training in heart failure with preserved ejection fraction: beyond proof-of-concept. J Am Coll Cardiol 58: 1792–1794, 2011.
124. Kitzman DW, Brubaker PH, Morgan TM, Stewart KP, Little WC. Exercise training in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. Circ Heart Fail 3: 659–667, 2010.
125. Klotz S, Barbone A, Reiken S, Holmes JW, Naka Y, Oz MC, Marks AR, Burkhoff D. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. J Am Coll Cardiol 45: 668–676, 2005.
126. Klotz S, Danser AH, Foronjy RF, Oz MC, Wang J, Mancini D, D’Armiento J, Burkhoff D. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 49: 1166–1174, 2007.
127. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyn-gborg K, Videbaek J, Cole DS, Auclert L, Pauly NC. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333: 1670–1676, 1995.
128. Koitabashi N, Aiba T, Hesketh GG, Rowell J, Zhang M, Takimoto E, Tomaselli GF, Kass DA. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomy-ocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 48: 713–724, 2010.
129. Koitabashi N, Kass DA. Reverse remodeling in heart failure–mecha-nisms and therapeutic opportunities. Nat Rev Cardiol 9: 147–157, 2012.
130. Konstantinou DM, Chatzizisis YS, Giannoglou GD. Pathophysiology-based novel pharmacotherapy for heart failure with preserved ejection fraction. Pharmacol Ther 140: 156–166, 2013.
131. Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62: 1330–1338, 2013.
132. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permea-bilization in cell death. Physiol Rev 87: 99–163, 2007.
133. Kruger M, Kotter S, Grutzner A, Lang P, Andresen C, Redfield MM, Butt E, dos Remedios CG, Linke WA. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res 104: 87–94, 2009.
134. Kruger M, Linke WA. Protein kinase-A phosphorylates titin in human heart muscle and reduces myofibrillar passive tension. J Muscle Res Cell Motil 27: 435–444, 2006.
135. Kuwabara Y, Horie T, Baba O, Watanabe S, Nishiga M, Usami S, Izuhara M, Nakao T, Nishino T, Otsu K, Kita T, Kimura T, Ono K. MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway. Circ Res 116: 279–288, 2015.
136. Kuwahara F, Kai H, Tokuda K, Kai M, Takeshita A, Egashira K, Imaizumi T. Transforming growth factor-beta function blocking pre-vents myocardial fibrosis and diastolic dysfunction in pressure-over-loaded rats. Circulation 106: 130–135, 2002.
137. Kuwahara F, Kai H, Tokuda K, Takeya M, Takeshita A, Egashira K, Imaizumi T. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? Hypertension 43: 739–745, 2004.
138. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 13: 18–28, 2011.
139. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 111: 1201–1209, 2003.
140. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activa-tion. Circ Res 106: 1675–1680, 2010.
141. Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, Bedja D, Kirk JA, Ranek MJ, Dostmann WR, Kwon C, Margulies KB, Van Eyk JE, Paulus WJ, Takimoto E, Kass DA. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519: 472–476, 2015.
142. Lee JF, Barrett-O’Keefe Z, Garten RS, Nelson AD, Ryan JJ, Nativi JN, Richardson RS, Wray DW. Evidence of microvascular dysfunction in heart failure with preserved ejection fraction. Heart (British Cardiac Society) 2015 Nov 13 [Epub ahead of print].
143. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prog-nostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561–1566, 1990.
144. LeWinter MM, Granzier H. Cardiac titin: a multifunctional giant. Circulation 121: 2137–2145, 2010.
145. Li C, Li X, Gao X, Zhang R, Zhang Y, Liang H, Xu C, Du W, Zhang Y, Liu X, Ma N, Xu Z, Wang L, Chen X, Lu Y, Ju J, Yang B, Shan H. MicroRNA-328 as a regulator of cardiac hypertrophy. Int J Cardiol 173: 268–276, 2014.
146. Li Z, Song Y, Liu L, Hou N, An X, Zhan D, Li Y, Zhou L, Li P, Yu L, Xia J, Zhang Y, Wang J, Yang X. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Diff 2015 Jul 10 [Epub ahead of print].
147. Lindqvist P, Bajraktari G, Molle R, Palmerini E, Holmgren A, Mondillo S, Henein MY. Valve replacement for aortic stenosis normal-izes subendocardial function in patients with normal ejection fraction. Eur J Echocardiogr 11: 608–613, 2010.
148. Linke WA, Granzier H. A spring tale: new facts on titin elasticity. Biophys J 75: 2613–2614, 1998.
149. Little WC, Zile MR, Kitzman DW, Hundley WG, O’Brien TX, Degroof RC. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11: 191–195, 2005.
150. Litwin SE, Katz SE, Weinberg EO, Lorell BH, Aurigemma GP, Douglas PS. Serial echocardiographic-Doppler assessment of left ven-tricular geometry and function in rats with pressure-overload hypertro-phy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. Circulation 91: 2642–2654, 1995.
151. Liu F, Chen Y, Feng X, Teng Z, Yuan Y, Bin J. Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysis. PLoS One 9: e90555, 2014.
152. Liu K, Ying Z, Qi X, Shi Y, Tang Q. MicroRNA-1 regulates the proliferation of vascular smooth muscle cells by targeting insulin-like growth factor 1. Int J Mol Med 36: 817–824, 2015.
153. 2+ signaling during the development of hypertrophy and heart failure. Circulation 130: 244–255, 2014.
154. Lombardi R, Betocchi S, Losi MA, Tocchetti CG, Aversa M, Mi-randa M, D’Alessandro G, Cacace A, Ciampi Q, Chiariello M. Myocardial collagen turnover in hypertrophic cardiomyopathy. Circula-tion 108: 1455–1460, 2003.
155. Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, Taglieri DM, Gu L, Kumar P, Pokhrel N, Zeng D, Belardinelli L, Sorescu D, Solaro RJ, Dudley SC Jr. Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensi-tivity. Circ Res 110: 841–850, 2012.
156. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83: 1201–1205, 1999.
157. Ma S, Wang Y, Chen Y, Cao F. The role of the autophagy in myocardial ischemia/reperfusion injury. Biochim Biophys Acta 1852: 271–276, 2015.
158. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, Lang C, Wachter R, Edelmann F, Hasenfuss G, Jacobshagen C. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 1: 115–122, 2013.
159. Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science (New York, NY) 331: 1439–1443, 2011.
160. Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the failing heart: myth, magic, or molecular target? J Am Coll Cardiol 2: 04774–04772, 2012.
161. Marks AR. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J Clin Invest 123: 46–52, 2013.
162. Marshall KD, Muller BN, Krenz M, Hanft LM, McDonald KS, Dellsperger KC, Emter CA. Heart failure with preserved ejection fraction: chronic low-intensity interval exercise training preserves myo-cardial O 2 balance and diastolic function. J Appl Physiol 114: 131–147, 2013.
163. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection frac-tion. N Engl J Med 359: 2456–2467, 2008.
164. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 83: 1182–1191, 1998.
165. Matsubara J, Sugiyama S, Nozaki T, Akiyama E, Matsuzawa Y, Kurokawa H, Maeda H, Fujisue K, Sugamura K, Yamamoto E, Matsui K, Jinnouchi H, Ogawa H. Incremental prognostic significance of the elevated levels of pentraxin 3 in patients with heart failure with normal left ventricular ejection fraction. J Am Heart Assoc 3: e000928, 2014.
166. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K, Matsuzawa Y, Akiyama E, Yamamoto E, Sakamoto K, Nagayoshi Y, Kaikita K, Sumida H, Kim-Mitsuyama S, Ogawa H. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am Coll Cardiol 57: 861–869, 2011.
167. Mattiazzi A, Kranias EG. The role of CaMKII regulation of phospho-lamban activity in heart disease. Front Pharmacol 5: 5, 2014.
168. Meyer M, McEntee RK, Nyotowidjojo I, Chu G, LeWinter MM. Relationship of exercise capacity and left ventricular dimensions in patients with a normal ejection fraction. An exploratory study. PLoS One 10: e0119432, 2015.
169. Michael SK, Surks HK, Wang Y, Zhu Y, Blanton R, Jamnongjit M, Aronovitz M, Baur W, Ohtani K, Wilkerson MK, Bonev AD, Nelson MT, Karas RH, Mendelsohn ME. High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci USA 105: 6702–6707, 2008.
170. Milano AD, Faggian G, Dodonov M, Golia G, Tomezzoli A, Borto-lotti U, Mazzucco A. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg 144: 830–837, 2012.
171. Mohamed BA, Schnelle M, Khadjeh S, Lbik D, Herwig M, Linke WA, Hasenfuss G, Toischer K. Molecular and structural transition mechanisms in long-term volume overload. Eur J Heart Fail 2015 Dec 23 [Epub ahead of print].
172. Molkentin JD, Lu JR, Antos CL, Markham B, Richardson J, Rob-bins J, Grant SR, Olson EN. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93: 215–228, 1998.
173. Monrad ES, Hess OM, Murakami T, Nonogi H, Corin WJ, Krayen-buehl HP. Time course of regression of left ventricular hypertrophy after aortic valve replacement. Circulation 77: 1345–1355, 1988.
174. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, Stack C, Latimer PA, Olson EN, van Rooij E. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124: 1537–1547, 2011.
175. Moorjani N, Ahmad M, Catarino P, Brittin R, Trabzuni D, Al-Mohanna F, Narula N, Narula J, Westaby S. Activation of apoptotic caspase cascade during the transition to pressure overload-induced heart failure. J Am Coll Cardiol 48: 1451–1458, 2006.
176. Morgan JA, Brewer RJ, Nemeh HW, Murthy R, Williams CT, Lanfear DE, Tita C, Paone G. Left ventricular reverse remodeling with a continuous flow left ventricular assist device measured by left ventric-ular end-diastolic dimensions and severity of mitral regurgitation. ASAIO J 58: 574–577, 2012.
177. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, Witt CC, Becker K, Labeit S, Granzier HL. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 110: 155–162, 2004.
178. Nair N, Kumar S, Gongora E, Gupta S. Circulating miRNA as novel markers for diastolic dysfunction. Mol Cell Biochem 376: 33–40, 2013.
179. Neubauer S. The failing heart–an engine out of fuel. N Engl J Med 356: 1140–1151, 2007.
180. Nochioka K, Sakata Y, Miyata S, Miura M, Takada T, Tadaki S, Ushigome R, Yamauchi T, Takahashi J, Shimokawa H. Prognostic impact of statin use in patients with heart failure and preserved ejection fraction. Circ J 79: 574–582, 2015.
181. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension A prospective, random-ized, comparison of the long-term effects of atenolol vs nebivolol. Eur J Heart Fail 5: 621–627, 2003.
182. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing human heart. N Engl J Med 336: 1131–1141, 1997.
183. Opie LH. Mechanisms of cardiac contraction and relaxation. In: Braun-wald’s Heart Disease, edited by Mann DL, Libby P, Bonow RO. Philadelphia, PA: Elsevier, 2014.
184. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 367: 356–367, 2006.
185. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflamma-tion. J Am Coll Cardiol 62: 263–271, 2013.
186. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J Clin Invest 116: 1547–1560, 2006.
187. Persson H, Lonn E, Edner M, Baruch L, Lang CC, Morton JJ, Ostergren J, McKelvie RS. Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES. J Am Coll Cardiol 49: 687–694, 2007.
188. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 57: 84–95, 1985.
189. Pfeffer MA. The Survival and Ventricular Enlargement (SAVE) study: rationale and perspective. Herz 18, Suppl 1: 430–435, 1993.
190. Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Muller K, Roessig L, Gheorghiade M. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SO-CRATES). Eur J Heart Fail 16: 1026–1038, 2014.
191. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburish-vili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370: 1383–1392, 2014.
192. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W, Gao E, Dasgupta A, Rengo G, Remppis A, Katus HA, Eckhart AD, Rabinowitz JE, Koch WJ. Stable myocardial-specific AAV6–S100A1 gene therapy results in chronic functional heart failure rescue. Circula-tion 115: 2506–2515, 2007.
193. Poulsen SH, Sogaard P, Nielsen-Kudsk JE, Egeblad H. Recovery of left ventricular systolic longitudinal strain after valve replacement in aortic stenosis and relation to natriuretic peptides. J Am Soc Echocar-diogr 20: 877–884, 2007.
194. 2+ exchanger (ncx) inhibitor Sea0400 on diastolic function in vivo and in vitro in a model of heart failure with preserved ejection fraction (Ab-stract). Circulation 130, Suppl 2: A18739, 2014.
195. Raskin A, Lange S, Banares K, Lyon RC, Zieseniss A, Lee LK, Yamazaki KG, Granzier HL, Gregorio CC, McCulloch AD, Omens JH, Sheikh F. A novel mechanism involving four-and-a-half LIM domain protein-1 and extracellular signal-regulated kinase-2 regulates titin phosphorylation and mechanics. J Biol Chem 287: 29273–29284, 2012.
196. Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernan-dez AF, Mascette AM, Braunwald E; RELAX Trial. Effect of phos-phodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309: 1268–1277, 2013.
197. Reil JC, Hohl M, Reil GH, Granzier HL, Kratz MT, Kazakov A, Fries P, Muller A, Lenski M, Custodis F, Graber S, Frohlig G, Steendijk P, Neuberger HR, Bohm M. Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction. Eur Heart J 34: 2839–2849, 2013.
198. Ridha H, Thurner PJ. Finite element prediction with experimental validation of damage distribution in single trabeculae during three-point bending tests. J Mech Behav Biomed Mater 27: 94–106, 2013.
199. Roe ND, Ren J. Nitric oxide synthase uncoupling: a therapeutic target in cardiovascular diseases. Vasc Pharmacol 57: 168–172, 2012.
200. Rogers FJ, Gundala T, Ramos JE, Serajian A. Heart failure with preserved ejection fraction. J Am Osteopath Assoc 115: 432–442, 2015.
201. Rohde D, Brinks H, Ritterhoff J, Qui G, Ren S, Most P. S100A1 gene therapy for heart failure: a novel strategy on the verge of clinical trials. J Mol Cell Cardiol 50: 777–784, 2011.
202. Schlender KK, Bean LJ. Phosphorylation of chicken cardiac C-protein by calcium/calmodulin-dependent protein kinase II. J Biol Chem 266: 2811–2817, 1991.
203. Schmidt U, Zhu X, Lebeche D, Huq F, Guerrero JL, Hajjar RJ. In vivo gene transfer of parvalbumin improves diastolic function in aged rat hearts. Cardiovasc Res 66: 318–323, 2005.
204. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, Coskun PE, Ladiges W, Wolf N, Van Remmen H, Wallace DC, Rabinovitch PS. Extension of murine life span by over-expression of catalase targeted to mitochondria. Science (New York, NY) 308: 1909–1911, 2005.
205. Schultz Jel J, Witt SA, Glascock BJ, Nieman ML, Reiser PJ, Nix SL, Kimball TR, Doetschman T. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109: 787–796, 2002.
206. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest 86: 1913–1920, 1990.
207. Schwarzl M, Hamdani N, Seiler S, Alogna A, Manninger M, Reilly S, Zirngast B, Kirsch A, Steendijk P, Verderber J, Zweiker D, Eller P, Hofler G, Schauer S, Eller K, Maechler H, Pieske BM, Linke WA, Casadei B, Post H. A porcine model of hypertensive cardiomyopathy: implications for heart failure with preserved ejection fraction. Am J Physiol Heart Circ Physiol 309: H1407–H1418, 2015.
208. Senni M, Gavazzi A, Oliva F, Mortara A, Urso R, Pozzoli M, Metra M, Lucci D, Gonzini L, Cirrincione V, Montagna L, Di Lenarda A, Maggioni AP, Tavazzi L. In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. Int J Cardiol 173: 163–169, 2014.
209. Sequeira V, Najafi A, McConnell M, Fowler ED, Bollen IA, Wust RC, dos Remedios C, Helmes M, White E, Stienen GJ, Tardiff J, Kuster DW, van der Velden J. Synergistic role of ADP and Ca(2+)in diastolic myocardial stiffness. J Physiol 593: 3899–3916, 2015.
210. Shah AM, Claggett B, Sweitzer NK, Shah SJ, Anand IS, O’Meara E, Desai AS, Heitner JF, Li G, Fang J, Rouleau J, Zile MR, Markov V, Ryabov V, Reis G, Assmann SF, McKinlay SM, Pitt B, Pfeffer MA, Solomon SD. Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardio-graphic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail 7: 740–751, 2014.
211. Shah KB, Kop WJ, Christenson RH, Diercks DB, Henderson S, Hanson K, Li SY, deFilippi CR. Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction. Clin Chem 57: 874–882, 2011.
212. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients + 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 101: 217–222, 2008.
213. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res 115: 79–96, 2014.
214. Sharma S, Liu J, Wei J, Yuan H, Zhang T, Bishopric NH. Repression of miR-142 by p300 and MAPK is required for survival signalling via gp130 during adaptive hypertrophy. EMBO Mol Med 4: 617–632, 2012.
215. Shibasaki Y, Nishiue T, Masaki H, Tamura K, Matsumoto N, Mori Y, Nishikawa M, Matsubara H, Iwasaka T. Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers. Hypertens Res 28: 787–795, 2005.
216. Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, Boulden BM, Widder J, Fredd S, Bernstein KE, Wolska BM, Dika-lov S, Harrison DG, Dudley SC Jr. Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation 121: 519–528, 2010.
217. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 380: 1387–1395, 2012.
218. Song L, Su M, Wang S, Zou Y, Wang X, Wang Y, Cui H, Zhao P, Hui R, Wang J. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med 18: 2266–2274, 2014.
219. Song XW, Li Q, Lin L, Wang XC, Li DF, Wang GK, Ren AJ, Wang YR, Qin YW, Yuan WJ, Jing Q. MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes. J Cell Physiol 225: 437–443, 2010.
220. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts–role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 45: 32–43, 2008.
221. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL, Crumbley AJ. A matrix metalloprotei-nase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102: 1944–1949, 2000.
222. Stelzer JE, Patel JR, Walker JW, Moss RL. Differential roles of cardiac myosin-binding protein C and cardiac troponin I in the myofi-brillar force responses to protein kinase A phosphorylation. Circ Res 101: 503–511, 2007.
223. Steppan J, Tran H, Benjo AM, Pellakuru L, Barodka V, Ryoo S, Nyhan SM, Lussman C, Gupta G, White AR, Daher JP, Shoukas AA, Levine BD, Berkowitz DE. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. Exp Geron-tol 47: 565–572, 2012.
224. Stride N, Larsen S, Hey-Mogensen M, Sander K, Lund JT, Gustafs-son F, Kober L, Dela F. Decreased mitochondrial oxidative phosphor-ylation capacity in the human heart with left ventricular systolic dys-function. Eur J Heart Fail 15: 150–157, 2013.
225. Sulaiman K, Panduranga P, Al-Zakwani I, Alsheikh-Ali AA, Al-Habib KF, Al-Suwaidi J, Al-Mahmeed W, AlFaleh H, Elasfar A, Al-Motarreb A, Ridha M, Bulbanat B, Al-Jarallah M, Bazargani N, Asaad N, Amin H. Clinical characteristics, management, and outcomes of acute heart failure patients: observations from the Gulf acute heart failure registry (Gulf CARE). Eur J Heart Fail 17: 374–384, 2015.
226. Sulaiman KJ, Panduranga P, Al-Zakwani I, Alsheikh-Ali A, Al-Habib K, Al-Suwaidi J, Al-Mahmeed W, Al-Faleh H, El-Asfar A, Al-Motarreb A, Ridha M, Bulbanat B, Al-Jarallah M, Bazargani N, Asaad N, Amin H. Rationale, design, methodology and hospital char-acteristics of the first Gulf Acute Heart Failure Registry (Gulf CARE). Heart Views 15: 6–12, 2014.
227. Sun M, Chen M, Dawood F, Zurawska U, Li JY, Parker T, Kassiri Z, Kirshenbaum LA, Arnold M, Khokha R, Liu PP. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115: 1398–1407, 2007.
228. Szatkowski ML, Westfall MV, Gomez CA, Wahr PA, Michele DE, DelloRusso C, Turner II, Hong KE, Albayya FP, Metzger JM. In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. J Clin Invest 107: 191–198, 2001.
229. Takimoto E. Cyclic GMP-dependent signaling in cardiac myocytes. Circ J 76: 1819–1825, 2012.
230. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hyper-trophy. Nat Med 11: 214–222, 2005.
231. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac patho-logic remodeling from chronic pressure load. J Clin Invest 115: 1221–1231, 2005.
232. Tamura T, Said S, Harris J, Lu W, Gerdes AM. Reverse remodeling of cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-angiotensin system. Circulation 102: 253–259, 2000.
233. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Kote-liansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhani-fard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980–984, 2008.
234. Tian R, Nascimben L, Ingwall JS, Lorell BH. Failure to maintain a low ADP concentration impairs diastolic function in hypertrophied rat hearts. Circulation 96: 1313–1319, 1997.
235. Timmermans PB, Wong PC, Chiu AT, Smith RD. The preclinical basis of the therapeutic evaluation of losartan. J Hypertens Suppl 13: S1–13, 1995.
236. Tong CW, Nair NA, Doersch KM, Liu Y, Rosas PC. Cardiac myosin-binding protein-C is a critical mediator of diastolic function. Pflügers Arch 466: 451–457, 2014.
237. Tong CW, Stelzer JE, Greaser ML, Powers PA, Moss RL. Acceler-ation of crossbridge kinetics by protein kinase A phosphorylation of cardiac myosin binding protein C modulates cardiac function. Circ Res 103: 974–982, 2008.
238. Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M. Prognostic impact of angiotensin-converting enzyme inhibitor ther-apy in diastolic heart failure. Am J Cardiol 101: 639–644, 2008.
239. Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. Circ Res 110: 295–303, 2012.
240. Ucar A, Gupta SK, Fiedler J, Erikci E, Kardasinski M, Batkai S, Dangwal S, Kumarswamy R, Bang C, Holzmann A, Remke J, Caprio M, Jentzsch C, Engelhardt S, Geisendorf S, Glas C, Hofmann TG, Nessling M, Richter K, Schiffer M, Carrier L, Napp LC, Bauersachs J, Chowdhury K, Thum T. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun 3: 1078, 2012.
241. Upadhya B, Haykowsky MJ, Eggebeen J, Kitzman DW. Exercise intolerance in heart failure with preserved ejection fraction: more than a heart problem. J Geriatr Cardiol 12: 294–304, 2015.
242. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: the cardiac burn-out syndrome? Cardio-vasc Res 61: 218–226, 2004.
243. van Heerebeek L, Borbely A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myo-cardial structure and function differ in systolic and diastolic heart failure. Circulation 113: 1966–1973, 2006.
244. van Heerebeek L, Hamdani N, Falcao-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126: 830–839, 2012.
245. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K, Ijsselmuiden AJ, Schalkwijk CG, Bronzwaer JG, Diamant M, Borbely A, van der Velden J, Stienen GJ, Laarman GJ, Niessen HW, Paulus WJ. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117: 43–51, 2008.
246. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105: 13027–13032, 2008.
247. Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol 113: 321–327, 2014.
248. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD. Beta-blockade with nebivolol in elderly heart failure patients with impaired and pre-served left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 53: 2150–2158, 2009.
249. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Levy D. Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 336: 1350–1355, 1997.
250. Villar AV, Merino D, Wenner M, Llano M, Cobo M, Montalvo C, Garcia R, Martin-Duran R, Hurle JM, Hurle MA, Nistal JF. Myo-cardial gene expression of microRNA-133a and myosin heavy and light chains, in conjunction with clinical parameters, predict regression of left ventricular hypertrophy after valve replacement in patients with aortic stenosis. Heart (British Cardiac Society) 97: 1132–1137, 2011.
251. Villari B, Hess OM, Meier C, Pucillo A, Gaglione A, Turina M, Krayenbuehl HP. Regression of coronary artery dimensions after suc-cessful aortic valve replacement. Circulation 85: 972–978, 1992.
252. Villari B, Vassalli G, Monrad ES, Chiariello M, Turina M, Hess OM. Normalization of diastolic dysfunction in aortic stenosis late after valve replacement. Circulation 91: 2353–2358, 1995.
253. Wahlquist C, Jeong D, Rojas-Munoz A, Kho C, Lee A, Mitsuyama S, van Mil A, Park WJ, Sluijter JP, Doevendans PA, Hajjar RJ, Mercola M. Inhibition of miR-25 improves cardiac contractility in the failing heart. Nature 508: 531–535, 2014.
254. Wang BW, Wu GJ, Cheng WP, Shyu KG. MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PloS one 9: e84188, 2014.
255. Wang K, Lin ZQ, Long B, Li JH, Zhou J, Li PF. Cardiac hypertrophy is positively regulated by microRNA miR-23a. J Biol Chem 287: 589–599, 2012.
256. Wang K, Long B, Zhou J, Li PF. miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. J Biol Chem 285: 11903–11912, 2010.
257. Watson CJ, Gupta SK, O’Connell E, Thum S, Glezeva N, Fendrich J, Gallagher J, Ledwidge M, Grote-Levi L, McDonald K, Thum T. MicroRNA signatures differentiate preserved from reduced ejection frac-tion heart failure. Eur J Heart Fail 17: 405–415, 2015.
258. Weber KT. Targeting pathological remodeling: concepts of cardiopro-tection and reparation. Circulation 102: 1342–1345, 2000.
259. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC Jr, Cruickshank JM, Devereux RB, Giles TD, Korsgaard N, Leier CV, Mendelsohn FA, Motz WH, Mulvany MJ, Strauder BE. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol 20: 3–16, 1992.
260. Weeks KL, McMullen JR. The athlete’s heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology (Bethesda) 26: 97–105, 2011.
261. Westaby S, Jin XY, Katsumata T, Taggart DP, Coats AJ, Frazier OH. Mechanical support in dilated cardiomyopathy: signs of early left ventricular recovery. Ann Thorac Surg 64: 1303–1308, 1997.
262. Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, Poller W, Schultheiss HP, Tschope C. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail 4: 44–52, 2011.
263. Westfall MV, Borton AR, Albayya FP, Metzger JM. Myofilament calcium sensitivity and cardiac disease: insights from troponin I isoforms and mutants. Circ Res 91: 525–531, 2002.
264. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 79: 359–366, 1987.
265. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E, Trautwein C, Lohmann SM, Drexler H. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39: 87–92, 2002.
266. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, Cohn JN. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 43: 2022–2027, 2004.
267. Wu C, Dong S, Li Y. Effects of miRNA-455 on cardiac hypertrophy induced by pressure overload. Int J Mol Med 35: 893–900, 2015.
268. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 106: 1384–1389, 2002.
269. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18: 1028–1040, 2012.
270. Xiao L, Zhao Q, Du Y, Yuan C, Solaro RJ, Buttrick PM. PKCepsilon increases phosphorylation of the cardiac myosin binding protein C at serine 302 both in vitro and in vivo. Biochemistry 46: 7054–7061, 2007.
271. Yamamoto K, Origasa H, Hori M. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15: 110–118, 2013.
272. Yamasaki R, Wu Y, McNabb M, Greaser M, Labeit S, Granzier H. Protein kinase A phosphorylates titin’s cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ Res 90: 1181–1188, 2002.
273. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the man-agement of heart failure: executive summary: a report of the AmericanCollege of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128: 1810–1852, 2013.
274. Yarbrough WM, Baicu C, Mukherjee R, Van Laer A, Rivers WT, McKinney RA, Prescott CB, Stroud RE, Freels PD, Zellars KN, Zile MR, Spinale FG. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hy-pertrophy. Am J Physiol Heart Circ Physiol 307: H752–H761, 2014.
275. Yu CM, Chau E, Sanderson JE, Fan K, Tang MO, Fung WH, Lin H, Kong SL, Lam YM, Hill MR, Lau CP. Tissue Doppler echocardio-graphic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure. Circulation 105: 438–445, 2002.
276. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362: 777–781, 2003.
277. Zhang ZH, Li J, Liu BR, Luo CF, Dong Q, Zhao LN, Zhong Y, Chen WY, Chen MS, Liu SM. MicroRNA-26 was decreased in rat cardiac hypertrophy model and may be a promising therapeutic target. J Car-diovasc Pharmacol 62: 312–319, 2013.
278. Zhou J, Shi H, Zhang J, Lu Y, Fu M, Ge J. Rationale and design of the beta-blocker in heart failure with normal left ventricular ejection fraction (beta-PRESERVE) study. Eur J Heart Fail 12: 181–185, 2010.
279. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circu-lation 105: 1503–1508, 2002.
280. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PERSERVE) trial. Circulation 121: 1393–1405, 2010.
281. Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE; I-PRESERVE Investigators. Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124: 2491–2501, 2011.
282. Zile MR, Kjellstrom B, Bennett T, Cho Y, Baicu CF, Aaron MF, Abraham WT, Bourge RC, Kueffer FJ. Effects of exercise on left ventricular systolic and diastolic properties in patients with heart failure and a preserved ejection fraction versus heart failure and a reduced ejection fraction. Circ Heart Fail 6: 508–516, 2013.